Yang P.,Peking Aniversity Third Hospital |
Wang J.,Peking Aniversity Third Hospital |
Dong F.,Peking Aniversity Third Hospital |
Jing H.-M.,Peking Aniversity Third Hospital |
Ke X.-Y.,Peking Aniversity Third Hospital
Journal of Leukemia and Lymphoma | Year: 2012
Objective To analyse treatments and prognostic factors of T cell non-Hodgkin lymphoma (T-NHL). Methods Ninety-one patients with T-NHL were retrospectively analyzed, and clinical features, histopathology, laboratory data were included in Kaplan-Meier and prognostic analysis. Results Median age was 38 years, 58 (63.7 %) had high-intermediate and high risk by IPI, 72 (79.1 %) presented with advanced stage disease, extranodal disease was present in 64.8 % of patients. The overall response rate (ORR) for the whole group was 63.8 %, and the estimated 3, 5-year ORR were 55.5 %, 41.3 % respectively. Compared with CHOP-like regimen, the addition of etoposide could improve the survival of patients, meanwhile radiation therapy could improve the outcome of patients with NK/T cell lymphoma and mediastinal bulky disease, and consolidation chemotherapy with HSCT could improve the survival and reduce the recurrence of patients. Clinical stage, B symptoms, ECOG score, the level of LDH, extranodal involvment, anemia, initial treatment outcome, IPI score, the level of serum albumin and fibrinogen were predictive to overall survival. Cox multivariate analysis showed initial treatment outcome and B symptoms were independent prognostic factors. IPI and m-PIT were useful for stratified patients into different prognostic risk groups. Conclusion T-NHL is a heterogeneous group of malignancies with an inferior long term outcome. New treatment modality needs to be explored for these patients, and new drugs and HSCT may be good choices.